Dr Vasant Narasimhan elected a member of the US National Academy of Medicine
Posted: 11 November 2015 |
The US National Academy of Medicine (NAM) recently announced the election of Dr Vasant “Vas” Narasimhan as a member of the Academy.
Dr Narasimhan is the only pharmaceutical industry representative on the 2015 list.
“I am honored to join the Academy and look forward to working with my fellow members and health policy makers on tackling the challenges facing patients and our health care system,” said Dr Narasimhan.
Global Head of Development at Novartis
Dr Narasimhan is Global Head of Development at Novartis where he oversees all functions and project teams related to new product development globally, most recently leading the approval of first in class molecules Entresto for heart failure and Cosentyx for psoriasis. Previously, he was Global Development Head at Novartis Vaccines where he oversaw the development and licensure of multiple first in class vaccines using novel cell and genetic technologies including Bexsero, Menveo, Flucelvax, Fluad, and multiple pandemic vaccines. Prior to joining Novartis, Dr Narasimhan worked on a range of public health initiatives focused on addressing global health inequities.
“Our newly elected members represent the brightest, most influential, and passionate people in health, science, and medicine in our nation and internationally,” said NAM President Dr Victor J. Dzau. “They are at the top of their fields and are committed to service. The expertise they bring to the organisation will help us respond to today’s most pressing health-related challenges and inform the future of health, science, and medicine. It is my privilege to welcome these distinguished individuals to the National Academy of Medicine.”
